OSIVAX
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.
OSIVAX
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2017-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.osivax.com
Total Employee:
11+
Status:
Active
Contact:
+33 4 37 65 55 03
Total Funding:
50.8 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Grant - Osivax
Anaxago
Anaxago investment in Series B - Osivax
Bpifrance
Bpifrance investment in Grant - Osivax
European Innovation Council
European Innovation Council investment in Series B - Osivax
European Innovation Council
European Innovation Council investment in Grant - Osivax
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series A - Osivax
Cédric Delorme
Cédric Delorme investment in Series A - Osivax
Anaxago
Anaxago investment in Series A - Osivax
Anaxago
Anaxago investment in Seed Round - Osivax
Official Site Inspections
http://www.osivax.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: cluster031.hosting.ovh.net
- IP address: 146.59.209.152
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "Osivax"
About Us - Osivax
Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to leverage both arms of the immune system: superior T-cell …See details»
Osivax - LinkedIn
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan …See details»
Osivax - Crunchbase Company Profile & Funding
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the …See details»
Osivax - Devex
Learn more about Osivax's jobs, projects, latest news, contact information and geographical presence. Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses.See details»
Osivax Company Profile 2024: Valuation, Funding & Investors
Osivax General Information Description. Developer of a universal vaccine designed to prevent globally impactful infectious diseases. The company's vaccine leverages its technology and …See details»
The Globe and Mail - The Globe and Mail
Mar 28, 2023 Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine. Business Wire - Tue Mar 28, 2023.See details»
Osivax Awarded Grant from a Leading Non-Governmental …
Mar 28, 2023 Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has …See details»
Osivax - European Commission - European Innovation Council
Osivax is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. Osivax is focused on providing proof …See details»
Osivax S.A.S. - BioCentury Company Profiles - BCIQ
Osivax S.A.S. - BioCentury Company Profiles for the biopharma industrySee details»
Osivax Company Profile: Overview and Full News Analysis
Osivax, located in Rhone-Alpes, is a company that focuses on developing universal vaccines against constantly mutating pathogens using their oligoDOM® self-assembling nanoparticles …See details»
Developing broad-spectrum vaccines that target the heart of …
Aug 3, 2022 Osivax, a French biotech, has developed its proprietary oligoDOM ® technology platform to elicit a T-cell immune response targeting the internal antigens of a virus. Its …See details»
Osivax begins phase 2a booster trial for influenza vaccine
Nov 14, 2024 Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious viruses, has vaccinated the first participant in its phase 2a clinical …See details»
Osivax - EU-Startups
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T …See details»
News - Osivax
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. Zhao X et al. npj Vaccines, 2024 Jun. 9:119. doi: 10.1038/s41541-024 …See details»
Osivax and KM Biologics Enter Exclusive License Option …
Sep 9, 2024 Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, and KM Biologics Co., Ltd., a …See details»
Research programme: cancer vaccines - OSIVAX - AdisInsight
OSIVAX is developing cancer vaccines using its proprietary oligoDOM® technology, used to trigger a powerful immune response. The technology uses a Research programme: cancer …See details»
Research programme: mRNA vaccines - Osivax - AdisInsight
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»
Pipeline - Osivax
Osivax is creating a pipeline of universal vaccines to revolutionize infectious disease prevention and meet a significant medical need. These vaccine candidates are based on the oligoDOM …See details»
Osivax Announces First Participant Vaccinated in Phase 2a Clinical ...
Nov 14, 2024 Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM TM, to develop transformative, first-in …See details»